Oculis
Nasdaq OCS · Zug, Switzerland
Works in Immunology · Neurology · Ophthalmology
Oculis is a clinical trial sponsor based in Zug, Switzerland, listed as Nasdaq OCS. It has 2 active clinical trials with 370 planned participants, in Immunology, Neurology and Ophthalmology. Since 2021 it has completed 7 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq OCS
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Oculis
Oculis is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 370 planned participants, in Immunology, Neurology, Ophthalmology. Since 2021 it has completed 7 trials and stopped 1 early.
Oculis is based in Zug, Switzerland and is listed as Nasdaq OCS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Oculis; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-28.
Approve Suite is not affiliated with Oculis.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.